The health and economic impact of scaling cervical cancer prevention in 50 low- and lower-middle-income countries

To expand coverage, or increase frequency: Quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low-resource settings

(2017) Nicole G. Campos et al.   INTERNATIONAL JOURNAL OF CANCER

Development assistance for health: past trends, associations, and the future of international financial flows for health

(2016) Joseph L Dieleman et al.   LANCET

Resources Required for Cervical Cancer Prevention in Low- and Middle-Income Countries

(2016) Nicole G. Campos et al.   PLoS One

Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis

(2016) Laia Bruni et al.   Lancet Global Health

The comparative and cost-effectiveness of HPV-based cervical cancer screening algorithms in El Salvador

(2015) Nicole G. Campos et al.   INTERNATIONAL JOURNAL OF CANCER

Cervical cancer screening in low-resource settings: A cost-effectiveness framework for valuing tradeoffs between test performance and program coverage

(2015) Nicole G. Campos et al.   INTERNATIONAL JOURNAL OF CANCER

A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women

(2015) Elmar A. Joura et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Updated Natural History Model of Cervical Cancer: Derivation of Model Parameters

(2014) Nicole G. Campos et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

In Reply to Sharma et al

(2014) Niloy R. Datta et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine

(2014) Paulo S Naud et al.   Human Vaccines & Immunotherapeutics

Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study

(2014) Mark Jit et al.   Lancet Global Health

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule

(2011) Barbara Romanowski et al.   Human vaccines & immunotherapeutics

Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication

(2010) Ni Li et al.   INTERNATIONAL JOURNAL OF CANCER

Expansion of cancer care and control in countries of low and middle income: a call to action

(2010) Paul Farmer et al.   LANCET

Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women

(2010) N. De Carvalho et al.   VACCINE

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

(2009) J Paavonen et al.   LANCET

Cancer survival in Africa, Asia, and Central America: a population-based study

(2009) Rengaswamy Sankaranarayanan et al.   LANCET ONCOLOGY

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries

(2008) Sue J. Goldie et al.   VACCINE

Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica

(2008) Rolando Herrero et al.   VACCINE